BGB-A445

CAT: 0804-HY-P991613Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-P991613Size:1 Each
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
BGB-A445 is a humanized non-ligand-blocking agonistic OX40 monoclonal antibody with high affinity to OX40. BGB-A445 activates downstream NF-κB pathway to induce immune cell activation, proliferation, and survival. BGB-A445 dose-dependently and significantly depletes regulatory T cells via antibody-dependent cellular cytotoxicity (ADCC) . BGB-A445 demonstrates robust and dose-dependent antitumor efficacy in the MC38 mice models. BGB-A445 can be used for the research of cancer, such as colon adenocarcinoma[1][2].
CAS Number
[3033874-57-3]
UNSPSC
12352203
Target
NF-κB; Orexin Receptor (OX Receptor)
Related Pathways
GPCR/G Protein; Neuronal Signaling; NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer
References & Citations
[1]Jiang B, et al. BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models. Front Med. 2023 Dec;17 (6) :1170-1185.|[2]Jiang B, et al. A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported

Related Products

CatalogName
HY-149051-01BGB-8035
HY-15732-01BGB-102

Alternative Products

CatalogName
T9901A-1817-01BGB-A445
T73381-01BGB-8035
BA6386-1BGB-102
JH914116BGB-15025
MBS5764893BGB-290
M39443-01BGB 15025
M11891-01BGB-283
OR1022841-01Zanubrutinib (BGB-3111)
A21288-10BGB-102 10mg
A21288-25BGB-102 25mg

Popular Products